001     169830
005     20240229133656.0
024 7 _ |a 10.1002/mp.15096
|2 doi
024 7 _ |a pmid:34260079
|2 pmid
024 7 _ |a 0094-2405
|2 ISSN
024 7 _ |a 1522-8541
|2 ISSN
024 7 _ |a 2473-4209
|2 ISSN
024 7 _ |a altmetric:109528381
|2 altmetric
037 _ _ |a DKFZ-2021-01574
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Marot, Mathieu
|0 P:(DE-He78)8b9e41d8fdbc77efc053f339f24458f2
|b 0
|e First author
|u dkfz
245 _ _ |a Technical Note: On the feasibility of performing dosimetry in target and organ at risk using polymer dosimetry gel and thermoluminescence detectors in an anthropomorphic, deformable and multimodal pelvis phantom.
260 _ _ |a College Park, Md.
|c 2021
|b AAPM
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1642167141_11420
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:E040#LA:E040# / 2021 Sep;48(9):5501-5510
520 _ _ |a To assess the feasibility of performing dose measurements in the target (prostate) and an adjacent organ at risk (rectum) using polymer dosimetry gel and thermoluminescence detectors (TLDs) in an anthropomorphic, deformable and multimodal pelvis phantom (ADAM PETer).The 3D printed prostate organ surrogate of the ADAM PETer phantom was filled with polymer dosimetry gel. Nine TLD600 (LiF:Mg,Ti) were installed in 3x3 rows on a specifically designed 3D-printed TLD holder. The TLD holder was inserted into the rectum at the level of the prostate and fixed by a partially inflated endorectal balloon. Computed tomography (CT) images were taken and treatment planning was performed. A prescribed dose of 4.5 Gy was delivered to the planning target volume (PTV). The doses measured by the dosimetry gel in the prostate and the TLDs in the rectum ('measured dose') were compared to the doses calculated by the treatment planning system ('planned dose') on a voxel-by-voxel basis.In the prostate organ surrogate, the 3D-γ-index was 97.7% for the 3% dose difference and 3 mm distance to agreement criterium. In the center of the prostate organ surrogate, measured and planned doses showed only minor deviations (<0.1 Gy, corresponding to a percentage error of 2.22%). On the edges of the prostate, slight differences between planned and measured doses were detected with a maximum deviation of 0.24 Gy, corresponding to 5.3% of the prescribed dose. The difference between planned and measured doses in the TLDs was on average 0.08 Gy (range: 0.02-0.21 Gy), corresponding to 1.78% of the prescribed dose (range: 0.44-4.67%).The present study demonstrates the feasibility of using polymer dosimetry gel and TLDs for 3D and 1D dose measurements in the prostate and the rectum organ surrogates in an anthropomorphic, deformable and multimodal phantom. The described methodology might offer new perspectives for end-to-end tests in image-guided adaptive radiotherapy workflows.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a 3D dosimetry
|2 Other
650 _ 7 |a TLD
|2 Other
650 _ 7 |a anthropomorphic phantom
|2 Other
650 _ 7 |a polymer dosimetry gel
|2 Other
650 _ 7 |a thermoluminescence dosimetry
|2 Other
700 1 _ |a Elter, Alina
|0 P:(DE-He78)d6ff1f04f2e927518e4290cc7dec3133
|b 1
|u dkfz
700 1 _ |a Mann, Philipp
|0 P:(DE-He78)d26409e0d07007daf771142a945102ef
|b 2
|u dkfz
700 1 _ |a Schwahofer, Andrea
|0 P:(DE-He78)8918404541688dee7976f7546be900fe
|b 3
|u dkfz
700 1 _ |a Lang, Clemens
|0 P:(DE-He78)2c5517db7bc397f9b14ae357a7ce54ff
|b 4
|u dkfz
700 1 _ |a Johnen, Wibke
|0 P:(DE-He78)5c55eb63ee2ad2499f7dda0ed08c571b
|b 5
|u dkfz
700 1 _ |a Körber, Stefan A
|b 6
700 1 _ |a Beuthien-Bauman, Bettina
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Gillmann, Clarissa
|0 P:(DE-He78)a7fec7d808abe2d2579a48df08c0f0ad
|b 8
|e Last author
|u dkfz
773 _ _ |a 10.1002/mp.15096
|g p. mp.15096
|0 PERI:(DE-600)1466421-5
|n 9
|p 5501-5510
|t Medical physics
|v 48
|y 2021
|x 2473-4209
909 C O |p VDB
|o oai:inrepo02.dkfz.de:169830
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)8b9e41d8fdbc77efc053f339f24458f2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)d6ff1f04f2e927518e4290cc7dec3133
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)d26409e0d07007daf771142a945102ef
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)8918404541688dee7976f7546be900fe
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)2c5517db7bc397f9b14ae357a7ce54ff
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)5c55eb63ee2ad2499f7dda0ed08c571b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)a7fec7d808abe2d2579a48df08c0f0ad
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-315
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Imaging and radiooncology
|x 0
914 1 _ |y 2021
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2021-02-02
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2021-02-02
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-02-02
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MED PHYS : 2019
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2021-02-02
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2021-02-02
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2021-02-02
920 1 _ |0 I:(DE-He78)E040-20160331
|k E040
|l E040 Med. Physik in der Strahlentherapie
|x 0
920 1 _ |0 I:(DE-He78)E010-20160331
|k E010
|l E010 Radiologie
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E040-20160331
980 _ _ |a I:(DE-He78)E010-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21